The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Screening system to identify 5 alpha reductase inhibitors
Benign Prostatic Hyperplasia (BHP) is a common condition affecting older men in which the prostate gland becomes enlarged, which could cause issues associated with urination. Androgenetic Alopecia (AGA) is the most common form of hair loss. Both diseases are mediated by androgens.
The main pathogenic androgen in those conditions (BHP and AGA) is dihydrotestosterone (DHT). DHT is a product of the conversion of testosterone by the enzyme 5-ɑ reductase (5AR).
There are two key isoforms of the 5-a reductase (5AR) enzyme, Type I and Type II. These are encoded by different genes. Understanding the variations in tissue distribution and functionality between these isoforms (Type I and Type II) is crucial for the development of targeted interventions for DHT regulation.
Our goal is to reduce DHT levels in targeted biological systems. This reduction can be achieved through various mechanisms, such as enzyme inhibition, a decrease in enzyme activity, or modulation of gene expression. Novel inhibitors have the potential to contribute to the development of therapies for conditions like BPH and AGA by targeting the overproduction of DHT.
We are seeking tools and screening capabilities (ideally high throughput in nature) to screen novel substances for their potential to inhibit 5-alpha reductase.
Deadline: Dec. 31, 2023
Funding is proposal dependent, but an accepted proposal could expect support in the range of 25,000 - 100,000 USD (milestone dependent) with the potential for follow on funding.